Leukemia & Lymphoma Society

Personalized medicine impacting study conduct

Sunday, January 1, 2017

As the analysis of genetic data is fast becoming a significant part of clinical research programs, both to enroll study participants and understand how drugs work, investigative sites are increasingly asked to collect genetic samples and conduct genetic screenings for clinical trials.

[Read More]

INC Research to manage Leukemia & Lymphoma Society umbrella trial

Friday, November 11, 2016

INC Research, a global phase I to IV CRO, has announced its involvement in The Leukemia & Lymphoma Society’s (LLS) recently-launched precision medicine Master Trial to treat acute myeloid leukemia (AML). The Beat AML Master Trial is breaking ground in a number of areas, including the first time a nonprofit organization is working with multiple biotech and pharma sponsors and other key collaborators to professionally operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML.

[Read More]

Stemline Therapeutics, Leukemia & Lymphoma Society collaborate

Wednesday, October 30, 2013

Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

[Read More]

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

[Read More]